Richard J. Willke, PhD, chief science officer of ISPOR, previews the discussions at the ISPOR 22nd Annual International Meeting, which will be held May 20-24 in Boston, Massachusetts, including topics on the future of health policy in the United States and social networking interventions.
Richard J. Willke, PhD, chief science officer of ISPOR, previews the discussions at the ISPOR 22nd Annual International Meeting, which will be held May 20-24 in Boston, Massachusetts, including topics on the future of health policy in the United States and social networking interventions.
Transcript
As ISPOR prepares for the annual meeting in Boston in May, how is it handling the uncertainty of an Affordable Care Act repeal? What other topics will the meeting focus on?
Our first plenary in Boston is going to feature a panel of 4 leading health economists. Two that have worked with the Democrats—Jonathan Gruber and David Cutler—and 2 that have tended to work with Republicans—Joe Antos and Gail Wilensky. Given what just happened [with the American Health Care Act] we expect it to be a very lively discussion.
Our second plenary is on the leading edge of how we look at healthcare behaviors. It's called "Social Networking Interventions and Population Health." And it's being given by Nicholas Christakis of Yale. I'm really anxious to hear that one. And our third one will be very aligned with what we talked about [at AMCP 2017]. The title is "When Do You Really Need Randomized Clinical Trials?" And we'll have Sebastian Schneeweiss and Rob Califf, who was just FDA commissioner, and Steven Goodman to talk about those topics.
Plus, about another 100 sessions on a variety of current scientific and policy topics. So we're really excited about it.
Neoadjuvant Chemotherapy Becomes Leading Initial Treatment for Advanced Epithelial Ovarian Cancer
October 22nd 2024By 2021, neoadjuvant chemotherapy followed by interval cytoreductive surgery became the most common initial treatment for patients with advanced epithelial ovarian cancer, overtaking primary cytoreductive surgery.
Read More
Insurance Insights: Dr Jason Shafrin Estimates DMD Insurance Value
July 18th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the July 2024 issue of The American Journal of Managed Care® that estimates the insurance value of novel Duchenne muscular dystrophy (DMD) treatment.
Listen
Delayed Diagnoses, Oxygen Therapy Use Linked to Worse Outcomes in Patients With Fibrotic ILD
October 21st 2024Posters presented at the CHEST 2024 annual meeting revealed that delays in diagnosing fibrotic interstitial lung disease (ILD) can negatively impact overall survival, while supplemental oxygen therapy may exacerbate clinical burdens through increased rates of acute exacerbations and hospitalizations.
Read More
From Polypharmacy to Personalized Care: Dr Nihar Desai Discusses Holistic Cardiovascular Care
May 30th 2024In this episode of Managed Care Cast, Nihar Desai, MD, MPH, cardiologist and vice chief of Cardiology at the Yale School of Medicine, discusses therapies for cardiovascular conditions as they relate to patient adherence, polypharmacy, and health access.
Listen
A Novel Approach to Chronic GVHD With Axatilimab: Dr Daniel Wolff
October 18th 2024The latest therapy approved to treat chronic graft-versus-host disease (GVHD) has a new target different than the other approved therapies. Daniel Wolff, MD, also discusses future research on axatilimab to treat chronic GVHD earlier.
Read More